Chief Executive Officer, Paragon Biosciences
Pete Buzy joined the company in 2014 as the Chief Operating Officer later moving into the role of President & Chief Executive Officer. Bringing with him over 25 years of successful executive management experience, Pete has grown the company into a premier CDMO with a leading position in gene therapy and next-generation vaccines. With expertise in growing companies and increasing their value, he has been instrumental in leading the company to successfully achieve double-digit growth by building a business that provides valuable end-to-end customized manufacturing through a collaborative partnership with its clients.
Prior to Paragon, Pete spent over 13 years as a senior executive at Martek Biosciences Corporation (NASDAQ: MATK), a leader in the innovation, development, production, and sale of high-value products from microbial sources. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization with over $470M in annual sales. Pete’s responsibilities also included overseeing a CMO business unit as well as managing annual R&D spending of over $6M including research activities in algal genomics and pharmaceutical cell line development. He also directed two significant GMP facility expansions totaling over $150M involving the addition of 200+ manufacturing employees during a two-year period.
While at Martek, as Executive Vice President & Chief Financial Officer, Pete successfully raised over $300M in both private and public financing. He successfully oversaw several large corporate acquisitions, collaborations, and licensing arrangements, cultivating company growth while setting the stage for Martek’s sale to Royal DSM NV in 2011 for nearly $1.1B. He also earned the 2011 Chief Financial Officer of the Year Award from the Technology Council of Maryland.
Prior to Martek, Pete spent 13-years at Ernst & Young, where he advanced to Partner in the Northern Virginia High Technology and Life Science Practice, serving a variety of private and publicly traded biotechnology companies. A member of Paragon’s Board of Directors, Pete received a BBA in Accounting, from Salisbury University in Maryland and serves on the Board and Executive Committees of the Technology Council of Maryland.